Tempest Therapeutics (TPST) - נפח מכירות חזוי

Tempest Therapeutics (TPST) develops targeted small-molecule drugs to modulate tumor immunity. The company's sales history and forecasts are based on the work of US laboratories and partnerships with clinics. The 0.00 level captures the current state of the metric. The business is currently preparing final tests for a liver cancer drug, seeking to attract external investors for joint financing.

Institutional capital evaluates Tempest Therapeutics (TPST) through the lens of the potential monetization of its oncology pipeline. This indicator compares market capitalization with expected revenue to identify the degree of asset overvaluation. By analyzing the organization's projected sales, the investor sees a correlation between price and fundamental expectations. For a biotech company with transparent management and clear regulatory milestones, such a metric confirms the validity of the valuation, making the asset more predictable.